KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsBuildingsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Biogen (BIIB) Receivables (2016 - 2026)

Biogen has reported Receivables over the past 18 years, most recently at $4.7 million for Q1 2026.

  • For Q1 2026, Receivables rose 20.51% year-over-year to $4.7 million; the TTM value through Mar 2026 reached $4.7 million, up 20.51%, while the annual FY2025 figure was $524.6 million, 6802.63% up from the prior year.
  • Receivables for Q1 2026 was $4.7 million at Biogen, down from $524.6 million in the prior quarter.
  • Over five years, Receivables peaked at $1.8 billion in Q3 2023 and troughed at $3.9 million in Q1 2025.
  • A 5-year average of $894.4 million and a median of $1.4 billion in 2024 define the central range for Receivables.
  • Biggest five-year swings in Receivables: plummeted 99.55% in 2023 and later soared 8448.42% in 2025.
  • Year by year, Receivables stood at $1.7 billion in 2022, then decreased by 2.51% to $1.7 billion in 2023, then fell by 15.58% to $1.4 billion in 2024, then tumbled by 62.66% to $524.6 million in 2025, then crashed by 99.1% to $4.7 million in 2026.
  • Business Quant data shows Receivables for BIIB at $4.7 million in Q1 2026, $524.6 million in Q4 2025, and $4.8 million in Q3 2025.